Abattis Terminates $600,000 Private Placement
VANCOUVER, March 11, 2013 /CNW/ - Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), announces that it will not be proceeding with its $600,000 non-brokered private placement as previously announced in its Press Release dated February 12, 2013 as it is canvassing other avenues of financing through strategic relationships to prevent any dilution for its shareholders.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.
More by this Source
Abattis Signs LOI With Crudessence Kombucha Inc. To License Infused, Blended Kombucha Tea
Mar 06, 2013, 07:23 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.